Similarly, intratumoral injection of HLA-A*02:01-restricted CMV495–503 peptide followed by its specific CTLs resulted in statistically significant tumor growth inhibition (P < 0.05) (Fig. 3g). Here, HLA-A is linked to neoplasm.